BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3255 related articles for article (PubMed ID: 7864299)

  • 1. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
    Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
    Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
    Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
    Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions.
    Bergman R; Shemer A; Levy R; Friedman-Birnbaum R; Trau H; Lichtig C
    Am J Dermatopathol; 1995 Dec; 17(6):547-50. PubMed ID: 8599466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AgNOR area measurements differentiate benign and malignant melanocytic lesions more accurately than simple counting.
    Gonzalez AP; Kumar D; Sánchez RL
    Am J Dermatopathol; 1994 Aug; 16(4):372-6. PubMed ID: 7526724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of estrogen receptors in dysplastic nevi and malignant melanoma.
    Lecavalier MA; From L; Gaid N
    J Am Acad Dermatol; 1990 Aug; 23(2 Pt 1):242-6. PubMed ID: 2212119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
    Googe PB; Flanigan KL; Miedema JR
    Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
    Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
    Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p-27 (kip1) in nevi and melanomas.
    Morgan MB; Cowper SE
    Am J Dermatopathol; 1999 Apr; 21(2):121-4. PubMed ID: 10218670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative activity of primary cutaneous melanocytic tumours.
    Kuwata T; Kitagawa M; Kasuga T
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphometric, DNA and PCNA in thin malignant melanomas.
    Björnhagen V; Månsson-Brahme E; Lindholm J; Mattsson A; Auer G
    Med Oncol Tumor Pharmacother; 1993; 10(3):87-94. PubMed ID: 7903405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating benign nevi from malignant melanoma using DNA microdensitometry and karyometry and maturation: a zonal comparison, correlation and multivariate analysis.
    Li LX; Crotty KA; Palmer AA; Kril JJ; Stankovic R; Scolyer RA; McCarthy SW
    Anal Quant Cytol Histol; 2002 Aug; 24(4):234-43. PubMed ID: 12199325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA ploidy and nuclear morphometry for the classification of dysplastic nevi.
    Williams RA; Baak JP; Meijer GA; Charlton IG
    Anal Quant Cytol Histol; 1999 Oct; 21(5):437-44. PubMed ID: 10560527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spitz's nevi with halo reaction: a histopathologic study of 17 cases.
    Harvell JD; Meehan SA; LeBoit PE
    J Cutan Pathol; 1997 Nov; 24(10):611-9. PubMed ID: 9449488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
    Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
    J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA ploidy in thin melanoma.
    Zardawi IM; Jarvis L; Hersey P; Francis L; Shaw H; Grace J
    Pathology; 1988 Jul; 20(3):243-6. PubMed ID: 3205595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCNA expression and nucleolar organizer regions in malignant melanoma and nevus cell nevus.
    Kanoko M; Ueda M; Ichihashi M
    Kobe J Med Sci; 1994 Aug; 40(3-4):107-23. PubMed ID: 7739200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
    Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
    Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis.
    Kapur P; Selim MA; Roy LC; Yegappan M; Weinberg AG; Hoang MP
    Mod Pathol; 2005 Feb; 18(2):197-204. PubMed ID: 15467715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 163.